CQDM announces the results of its 2009-2010 competition

Quebec Consortium for Drug Discovery (CQDM) has chosen 5 exceptional projects for a total investment of $7.8 M distributed among 4 companies and 4 universities in Québec. Through enabling tools and technologies, these projects will allow the acceleration of new drugs discovery in several therapeutic areas. All selected projects went through an extensive evaluation process involving, among others, an assessment by an independent panel of scientific and industrial experts organized by the Fonds de la Recherche en Santé du Québec (FRSQ) and a risk analysis performed by CQDM. Two McGill projects chosen are: Identifying new synthetic lethality opportunities for the discovery of new therapeutic approaches in oncology (Gordon Shore, McGill University); Developing a novel approach based on phages in order to accelerate the screening for antiherpetic molecules (Matthias Götte, McGill University)